OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)-- OS Therapies Inc. (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial results ended March 31, 2025 and provided a business update.
'The first quarter of 2025 was a crucial execution quarter for OS Therapies, as we announced positive data from our OST-HER2 Phase 2b clinical trial in the prevention of recurrent, fully resected, lung metastatic pediatric osteosarcoma and will be leveraging this data to seek Accelerated Approval from the FDA and other regulatory authorities,' said Paul Romness, MHP, Chairman & CEO of OS Therapies. 'Additionally, we consolidated ownership of the listeria immunotherapy platform, adding three clinical stage and eight preclinical assets to our pipeline. We extended the exclusivity protection for its commercial runway into 2040 with the issuance of a new manufacturing patent. Additionally, we have secured research coverage from Wall Street analysts who have shown significant interest in the revival of the listeria immunotherapy platform. We have started important interactions with the FDA with a view towards an Accelerated Approval, with the Osteosarcoma community supporting in the ongoing FDA process. We believe we are well positioned to bring the first new treatment for osteosarcoma to market in over 40 years.'
'As outlined in communications surrounding our 2024 Annual Report on Form 10-K, the first quarter saw some significant one-time expenses related to closing out the treatment phase of the Phase 2b trial, as well as start-up costs for regulatory preparations ahead of our submission,' said Chris Acevedo, Chief Financial Officer of OS Therapies. 'Those one-time expenses are now largely behind us, and we have dramatically reduced our burn rate, positioning us to operate into mid-2026.'
First Quarter 2025 Corporate Highlights:
Reported positive data for our Phase 2b clinical trial of OST-HER2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare pediatric indication
Announced agreement to acquire three clinical stage, eight preclinical stage and all intellectual property surrounding the listeria cancer immunotherapy platform from Ayala Pharmaceuticals
Initiated manufacturing protocols to support the commercial launch of OST-HER2
Received a Notice of Allowance from the US Patent & Trademark Office related to the pending issuance of a patent protecting a new commercial manufacturing process for the listeria cancer immunotherapy platform into 2040
Formed subsidiary OS Drug Conjugates (OSDC) to create a focused business development opportunity for the Company's proprietary pH-sensitive tunable Antibody Drug Conjugates and tunable Drug Conjugates platform
Secured a Scientific Advice Meeting with the UK Medicines and Healthcare products Regulatory Agency to discuss seeking approval in the UK for OST-HER2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma
Received the keynote presentation at the osteosarcoma community's leading conference MIB Factor for June 28, 2025 in Salt Lake City, Utah
Second Quarter 2025 Progress to Date and Future Milestones
Progress to Date:
Secured a Type D meeting with the FDA to gain alignment on the statistical analysis plan for the OST-HER2 trial needed to support pending Accelerated Approval, Regenerative Medicine Advanced Therapy and Breakthrough Therapy designation requests
Completed the acquisition of the listeria cancer immunotherapy clinical, preclinical and IP assets from Ayala Pharmaceuticals
Announced positive data from canine osteosarcoma trials expanding the potential use of OST-HER2 into the prevention of amputation and control of lung metastases
Reported the formal issuance of the patent protecting proprietary commercial manufacturing methods for the listeria cancer immunotherapy platform
Formed subsidiary OS Animal Health to focus on commercialization of OST-HER2 in canine osteosarcoma
Upcoming 2025 Milestones:
Feedback from Type D meeting with the FDA on the proposed statistical analysis plan of the OST-HER2 osteosarcoma program that will be used to support pending Accelerated Approval, Regenerative Medicine Advanced Therapy and Breakthrough Therapy designation requests on or before June 16, 2025
Presentation of the OST-HER2 Phase 2b osteosarcoma program data analyzed based upon FDA feedback at MIB Factor on June 28, 2025
End of Phase 2 Meeting with FDA in Q3 2025 to review OST-HER2 Phase 2b osteosarcoma program data
Projected BLA submission in Q3 2025 for OST-HER2 in the prevention of recurrent, fully resected, lung metastatic pediatric osteosarcoma
Summer 2025 Scientific Advice Meeting (SAM) with MHRA for OST-HER2 osteosarcoma program, ILAP application submission and MHRA Conditional Marketing Authorisation application & decision
EMA National Competent Authority Scientific Advice Meeting Request (Medicines Evaluation Board, Netherlands) for OST-HER2 osteosarcoma program, EMA PRIME, EMA-FDA Parallel Scientific Advice application and EMA Conditional Marketing Authorisation application & decision
USDA meeting for OST-HER2 canine osteosarcoma program, conditional approval and initiation of pivotal clinical studies in preventive and therapeutic applications of OST-HER2 in osteosarcoma via subsidiary OS Animal Health
Loss from Operations:
The Company recorded a net operating loss of $3.876 million in the first quarter of 2025 compared with a net operating loss of $1.490 million in the first quarter of 2024. The increase in net loss was largely due to expenses associated with closing of the OST-HER2 Phase 2b osteosarcoma trial and expenses associated with initiating regulatory affairs activities associated with seeking Accelerated Approval with US FDA for OST-HER2 in osteosarcoma. Net loss per share in the first quarter of 2025 was $0.18 on 21.249 million weighted average shares outstanding compared to first quarter of 2024 where the Company delivered a loss of $0.25 per share on 5.991 million weighted average shares outstanding.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and other risks and uncertainties described in 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
24 minutes ago
- Business Upturn
Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries
By Business Wire India Published on June 23, 2025, 16:23 IST TOKYO, Japan & MALVERN, Pa., United States: H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter 'Fujirebio') today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter 'Plasma Services Group'). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The company is particularly well positioned in the field of rare diseases. From its state-of-the-art FDA registered, ISO certified facility in Moorestown, NJ, USA, Plasma Services Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. For more information about Plasma Services Group please visit 'We are excited to welcome Plasma Services Group, a company that has gained a solid reputation as a reliable global supplier of difficult-to-obtain biological raw materials to the life sciences industry, to the Fujirebio group of companies,' says Goki Ishikawa, President & CEO of Fujirebio Holdings, Inc. 'Current and future IVD and life science partners of Fujirebio and Plasma Services Group will benefit from the synergies in our combined offer of rare samples and biological materials, which in turn further reinforce Fujirebio's position in the market as a trusted CDMO partner.' 'For over 20 years our mission at PSG has always been rooted in serving our customers with care, integrity, and a commitment to quality,' said Nichelle Fernandez, President of Plasma Services Group. 'This next chapter with Fujirebio is deeply meaningful. It allows us to stay true to who we are while preserving the personal, responsive service our customers value. Together, we're positioned to offer even stronger support for the scientists and innovators who rely on us. Our shared commitment to consistency will have a lasting impact across the global IVD landscape.' Advisors Houlihan Lokey acted as exclusive financial advisor to Fujirebio. Achelous Partners acted as exclusive financial advisor to Plasma Services Group. About Fujirebio Fujirebio is global R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value CDMO partnerships with many of the world's leading diagnostic companies, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of more information about Fujirebio, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Business Upturn
24 minutes ago
- Business Upturn
IFF Opens New State-of-the-art Office in Hyderabad, India
By Business Wire India Published on June 23, 2025, 15:20 IST Hyderabad, India: IFF (NYSE: IFF)–a global leader in flavors, fragrances, food ingredients, health and biosciences—has officially relocated its Global Business Services (GBS) center in Hyderabad to a newly constructed, state-of-the-art facility. This move marks a significant step in IFF's strategy to drive operational excellence and innovation through agile corporate functions. The new 75,000 sq. ft. office located in Hyderabad's prime financial district, is designed to accommodate up to 600 employees. It features cutting-edge infrastructure, collaborative workspaces and advanced technologies that support IFF's global operations. This press release features multimedia. View the full release here: 'This move enables us to serve our customers with greater speed, efficiency and purpose, while advancing strategic growth and sustainability,' said Mike DeVeau, IFF CFO. 'It's a reflection of our commitment to building a future-ready, innovation-driven workplace. The heart of Hyderabad is also rich in tradition and modernity, which is an energy that fuels our mission to make joy through science, creativity and heart.' The Hyderabad center joins a growing network of IFF innovation and business hubs worldwide. It is well positioned to tap into the region's vibrant tech ecosystem and deep talent pool. The facility includes an Innovation Studio for experimentation in automation, robotics and artificial intelligence, with further enhancements planned to boost productivity and collaboration. Sustainability and inclusivity are at the heart of the design. The office incorporates solar lighting, rainwater harvesting and is on track for LEED Gold certification. It also features high-speed connectivity, advanced security systems and ergonomic, flexible workspaces tailored to diverse work styles. 'Our people are our greatest asset,' said Deborah Borg, IFF Chief People & Culture Officer. 'The new center was thoughtfully designed to provide a welcoming space for collaboration, wellness and innovation. This vibrant new office in one of IFF's key markets will be an important enabler to supporting future growth in India and for the company globally.' Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human more at LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Business Wire
37 minutes ago
- Business Wire
Three Leading Proxy Advisors Recommend ECAT Shareholders Support Board Nominees and Oppose Saba's Termination Proposal Ahead of June 26 Annual Meeting
NEW YORK--(BUSINESS WIRE)--BlackRock Advisors, LLC ('BlackRock') announced today that Egan-Jones recommended that shareholders of BlackRock ESG Allocation Term Trust (NYSE: ECAT) (the 'Fund') vote on the WHITE card FOR all ten incumbent Board nominees and AGAINST the proposal put forth by a dissident shareholder to terminate BlackRock as investment adviser at the Fund's annual meeting on June 26, 2025. In making its recommendation, Egan-Jones opposed the dissident's full slate of eight nominees. Egan-Jones joins Institutional Shareholder Services ('ISS') and Glass Lewis as the third independent proxy advisory firm to recommend shareholders vote in favor of incumbent Board nominees and against the proposal put forth by the dissident. Important statements in the Egan-Jones report include 1: '…we recommend shareholders vote on the WHITE proxy card FOR all 10 management nominees and AGAINST Saba's shareholder proposal to terminate the investment management agreement.' 'ECAT's shareholder returns have been superior compared to peers.' 'We believe that Saba Capital has not made a compelling case to terminate the Investment Management Agreement. In our view, the Fund has benefited from BlackRock's extensive expertise as an investment advisor for years, and as such termination of the agreement will be detrimental to the Fund's future state. We believe that approval of the proposal is not in the best interests of the Fund and its shareholders.' As previously announced, ISS and Glass Lewis recommended shareholders vote on the WHITE proxy card FOR Board nominees and AGAINST the termination proposal, and that they do NOT vote on the dissident's gold proxy card. VOTE FOR ALL BOARD NOMINEES AND AGAINST TERMINATION ON THE WHITE PROXY CARD TODAY Only your latest dated proxy will count at the meeting. Please do NOT send back any proxy card other than the one you receive from BlackRock as this will cancel your prior vote for the Board nominees. If you have already sent back a gold proxy card, you can still change your vote by (1) using the website provided on the WHITE proxy card; (2) calling the toll-free number provided on the WHITE proxy card; or (3) promptly completing, signing, dating and returning the WHITE proxy card. Any of these actions will replace the proxy card you previously completed. If you have any questions about the nominees or proposals to be voted on, please call Georgeson LLC, the firm assisting us in the solicitation of proxies, toll free at (866) 441-6128. The Fund's letters, proxy statement and proxy card for the annual meeting of shareholders to be held on June 26, 2025 are available at More information about ECAT may be found here: 1 Permission to use quotes was neither sought nor obtained.
